• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer?

作者信息

Yanagisawa Yoko, Midgley Rachel S

出版信息

Nat Rev Clin Oncol. 2010 Oct;7(10):556-7. doi: 10.1038/nrclinonc.2010.140.

DOI:10.1038/nrclinonc.2010.140
PMID:20877418
Abstract
摘要

相似文献

1
Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer?
Nat Rev Clin Oncol. 2010 Oct;7(10):556-7. doi: 10.1038/nrclinonc.2010.140.
2
Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.贝伐单抗治疗晚期结直肠癌：对当前范式的挑战。
J Clin Oncol. 2008 Oct 1;26(28):4693-4; author reply 4694-5. doi: 10.1200/JCO.2008.18.8060.
3
Chemotherapy and immunotherapy in metastatic colorectal cancer.转移性结直肠癌的化疗与免疫治疗
N Engl J Med. 2009 May 14;360(20):2134; author reply 2135-6. doi: 10.1056/NEJMc090489.
4
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.一项关于卡培他滨、奥沙利铂和贝伐单抗联合或不联合西妥昔单抗用于一线晚期结直肠癌的随机III期研究，即荷兰结直肠癌组（DCCG）的CAIRO2研究。毒性的中期分析。
Ann Oncol. 2008 Apr;19(4):734-8. doi: 10.1093/annonc/mdm607. Epub 2008 Feb 13.
5
Common side effects and interactions of colorectal cancer therapeutic agents.结直肠癌治疗药物的常见副作用及相互作用。
J Pract Nurs. 2011 Spring;61(1):7-20.
6
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.伊立替康联合持续静脉输注、大剂量推注或口服氟嘧啶用于转移性结直肠癌一线治疗的随机对照试验：BICC-C研究的更新结果
J Clin Oncol. 2008 Feb 1;26(4):689-90. doi: 10.1200/JCO.2007.15.5390.
7
First-line treatment of advanced colorectal cancer.晚期结直肠癌的一线治疗。
Lancet. 2011 Jun 18;377(9783):2060-2. doi: 10.1016/S0140-6736(11)60788-5. Epub 2011 Jun 5.
8
Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen.贝伐单抗联合伊立替康和卡培他滨用于晚期结直肠癌：一种耐受性良好、有效且便捷的治疗方案。
Anticancer Res. 2008 Sep-Oct;28(5B):3087-92.
9
Targeted therapy for advanced colorectal cancer--more is not always better.晚期结直肠癌的靶向治疗——并非越多越好。
N Engl J Med. 2009 Feb 5;360(6):623-5. doi: 10.1056/NEJMe0809343.
10
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.卡培他滨、贝伐珠单抗和丝裂霉素在转移性结直肠癌一线治疗中的应用：澳大利亚胃肠试验组随机 III 期 MAX 研究的结果。
J Clin Oncol. 2010 Jul 1;28(19):3191-8. doi: 10.1200/JCO.2009.27.7723. Epub 2010 Jun 1.

本文引用的文献

1
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.卡培他滨、贝伐珠单抗和丝裂霉素在转移性结直肠癌一线治疗中的应用：澳大利亚胃肠试验组随机 III 期 MAX 研究的结果。
J Clin Oncol. 2010 Jul 1;28(19):3191-8. doi: 10.1200/JCO.2009.27.7723. Epub 2010 Jun 1.
2
Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review.贝伐珠单抗联合化疗治疗晚期结直肠癌患者：系统评价。
Ann Oncol. 2010 Jun;21(6):1152-1162. doi: 10.1093/annonc/mdp533. Epub 2009 Nov 25.
3
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
贝伐单抗联合奥沙利铂为基础的化疗作为转移性结直肠癌的一线治疗：一项随机III期研究。
J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930.
4
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.卡培他滨联合奥沙利铂与氟尿嘧啶/亚叶酸钙联合奥沙利铂作为转移性结直肠癌一线治疗的随机III期研究。
J Clin Oncol. 2008 Apr 20;26(12):2006-12. doi: 10.1200/JCO.2007.14.9898.
5
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.伊立替康联合持续静脉输注、大剂量推注或口服氟嘧啶用于转移性结直肠癌一线治疗的随机对照试验：BICC-C研究结果
J Clin Oncol. 2007 Oct 20;25(30):4779-86. doi: 10.1200/JCO.2007.11.3357.
6
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.贝伐单抗联合奥沙利铂、氟尿嘧啶和亚叶酸钙（FOLFOX4）用于既往治疗过的转移性结直肠癌：东部肿瘤协作组E3200研究结果
J Clin Oncol. 2007 Apr 20;25(12):1539-44. doi: 10.1200/JCO.2006.09.6305.
7
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.疗效的联合分析：在氟尿嘧啶/亚叶酸钙治疗中添加贝伐单抗可提高转移性结直肠癌患者的生存率。
J Clin Oncol. 2005 Jun 1;23(16):3706-12. doi: 10.1200/JCO.2005.00.232. Epub 2005 May 2.
8
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.贝伐单抗联合伊立替康、氟尿嘧啶和亚叶酸钙治疗转移性结直肠癌。
N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691.
9
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.用抗血管生成疗法使肿瘤血管正常化：联合治疗的新范例。
Nat Med. 2001 Sep;7(9):987-9. doi: 10.1038/nm0901-987.
10
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.口服卡培他滨与静脉注射氟尿嘧啶加亚叶酸钙作为605例转移性结直肠癌患者一线治疗的比较：一项随机III期研究的结果
J Clin Oncol. 2001 Apr 15;19(8):2282-92. doi: 10.1200/JCO.2001.19.8.2282.